HealthMore in Health→
Chinese CRISPR Therapy Signals a More Competitive Global Gene-Medicine Market
Key Takeaways
- Endpoints reports that five beta thalassemia patients no longer need regular transfusions after a Chinese CRISPR therapy.
- The result suggests Chinese biotech could become more competitive in genetic medicine.
- The evidence is early, but the pricing and market implications could be significant.
DE
DT Editorial Team··via endpoints.news